Literature DB >> 17656368

Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin.

Xiang Ling1, Qiuying Cheng, Jennifer D Black, Fengzhi Li.   

Abstract

It has been previously shown that both survivin and the survivin splice variant survivin-2B are localized in mitochondria. Whereas the mechanism involved in blockade of mitochondria-mediated apoptosis by survivin has been extensively studied, the role of survivin-2B in regulation of apoptosis has not been well defined. In the present study, we report that in addition to mitochondria, survivin-2B is also localized in the microtubule organization center (MTOC) and, in contrast to other survivin isoforms (i.e. survivin and survivin-DeltaEx3), behaves as a proapoptotic molecule. We show that forced expression of survivin-2B blocks tubulin polymerization, ablates mitotic cells, and induces mitochondria-dependent apoptosis. The mitochondria-mediated apoptosis induced by survivin-2B was indicated by Smac release from mitochondria, activation of caspases 9 and 3, and loss of mitochondrial potential, while caspase-8 remained inactive. Further analysis of the mechanism for the mitochondria-associated events of apoptosis induced by forced expression of survivin-2B revealed down-regulation of the pro-survival factor Bcl-2 and up-regulation of the pro-apoptotic factor Bax in mitochondria, while the apoptosis-inducing factor (AIF) remains unchanged. Our studies further showed that taxol (paclitaxel) treatment of cancer cells not only up-regulates survivin but also down-regulates survivin-2B and that forced expression of survivin-2B sensitizes cells to taxol-induced cell growth inhibition and cell death, while silencing of endogenous survivin-2B transcripts by survivin-2B-specific siRNA made cells resistant to taxol treatment. These findings advance our current knowledge about survivin-2B and may help to develop novel approaches for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656368      PMCID: PMC2827256          DOI: 10.1074/jbc.M705161200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Conformation of the Bax C-terminus regulates subcellular location and cell death.

Authors:  A Nechushtan; C L Smith; Y T Hsu; R J Youle
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

Review 2.  Gamma-tubulin complexes and their interaction with microtubule-organizing centers.

Authors:  C Wiese; Y Zheng
Journal:  Curr Opin Struct Biol       Date:  1999-04       Impact factor: 6.809

3.  Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity.

Authors:  Jianguo Wu; Xiang Ling; Dalin Pan; Pasha Apontes; Lei Song; Ping Liang; Dario C Altieri; Terry Beerman; Fengzhi Li
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

4.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct. Expression in antifolate-sensitive and -resistant human cell lines.

Authors:  J J McGuire; C A Russell; M Balinska
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

6.  Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC).

Authors:  Xiang Ling; Jie Yang; Dongfeng Tan; Nithya Ramnath; Tallal Younis; Brian N Bundy; Harry K Slocum; Lily Yang; Muxiang Zhou; Fengzhi Li
Journal:  Lung Cancer       Date:  2005-09       Impact factor: 5.705

7.  Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines.

Authors:  Fengzhi Li; Xiang Ling; Huayi Huang; Lisa Brattain; Pasha Apontes; Jianguo Wu; Lise Binderup; Michael G Brattain
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

8.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function.

Authors:  F Li; E J Ackermann; C F Bennett; A L Rothermel; J Plescia; S Tognin; A Villa; P C Marchisio; D C Altieri
Journal:  Nat Cell Biol       Date:  1999-12       Impact factor: 28.824

9.  Control of apoptosis and mitotic spindle checkpoint by survivin.

Authors:  F Li; G Ambrosini; E Y Chu; J Plescia; S Tognin; P C Marchisio; D C Altieri
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

Review 10.  Role of survivin and its splice variants in tumorigenesis.

Authors:  F Li
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  22 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

2.  Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Authors:  Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

3.  Transcriptional upregulation of HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression.

Authors:  Erina Suzuki; Sabine Kajita; Hiroyuki Takahashi; Toshihide Matsumoto; Tomoko Tsuruta; Makoto Saegusa
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

4.  Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo.

Authors:  Xiang Ling; David Westover; Felicia Cao; Shousong Cao; Xiang He; Hak-Ryul Kim; Yuesheng Zhang; Daniel Cf Chan; Fengzhi Li
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

6.  Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor.

Authors:  Lei Tang; Xiang Ling; Wensheng Liu; Gokul M Das; Fengzhi Li
Journal:  Biochem Biophys Res Commun       Date:  2012-04-06       Impact factor: 3.575

Review 7.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

8.  Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo.

Authors:  Robert A Fenstermaker; Sheila A Figel; Jingxin Qiu; Tara A Barone; Sanam S Dharma; Evan K Winograd; Phillip M Galbo; Laura M Wiltsie; Michael J Ciesielski
Journal:  Clin Cancer Res       Date:  2018-03-14       Impact factor: 12.531

9.  Nuclear degradation of Wilms tumor 1-associating protein and survivin splice variant switching underlie IGF-1-mediated survival.

Authors:  Theodore W Small; J Geoffrey Pickering
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

10.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.